Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKB-9778 Ophthalmic Solution Safety and PK/PD Study
NCT04284514Phase 1Completed
- Sponsor
- Aerpio Therapeutics
- Start
- May 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in primary open-angle glaucoma (POAG) and ocular hypertension comparing AKB-9778 Ophthalmic Solution with Vehicle Control (2 arms). Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Vital sign- systolic and diastolic blood pressure and 1 more. Started May 2019; status: completed.
02
Drugs
razuprotafib
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT04284514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284514.